Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Xiangsheng Zuo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-8593-1132; OpenAlex author ID A5016021846. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. PPARδ: An underappreciated tumor accelerator in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2026.218385↗
  2. CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-25-1201↗
  3. A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-2098↗
  4. Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of Pancreatic Cancer Cells Through Inhibition of MUC1 Expression. Co-author DOI 10.1007/s10620-023-07931-3↗
  5. Vitamin D: Promises on the Horizon and Challenges Ahead for Fighting Pancreatic Cancer. Co-author DOI 10.3390/cancers13112716↗
  6. Ppard Is Essential in Acceleration of Pancreatic Ductal Adenocarcinoma Development by High-Fat Diet in Mutant Kras Mice Co-author DOI 10.1101/2020.12.04.412320↗
  7. DNA-Methyltransferase 1 Induces Dedifferentiation of Pancreatic Cancer Cells through Silencing of Krüppel-Like Factor 4 Expression. Co-author DOI 10.1158/1078-0432.ccr-17-0387↗
  8. KLF4-Mediated Suppression of CD44 Signaling Negatively Impacts Pancreatic Cancer Stemness and Metastasis. Co-author DOI 10.1158/0008-5472.can-15-1691↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daoyan Wei · 8 shared papers, 2016–2026 · strength 1.53
  2. Liang Wang · 4 shared papers, 2021–2025 · strength 0.96
  3. Robert S. Bresalier · 4 shared papers, 2021–2025 · strength 0.96
  4. Yi Liu · 4 shared papers, 2020–2026 · strength 0.94
  5. Imad Shureiqi · 2 shared papers, 2020–2026 · strength 0.45
  6. James C. Yao · 2 shared papers, 2020–2026 · strength 0.45
  7. Danping Niu · 1 shared paper, 2026 · strength 0.36
  8. Xiling Shen · 1 shared paper, 2025 · strength 0.30
  9. Anirban Maitra · 1 shared paper, 2024 · strength 0.28
  10. Peiying Yang · 1 shared paper, 2023 · strength 0.18
  11. Zhiwei Li · 2 shared papers, 2016–2017 · strength 0.12
  12. Yongmin Yan · 2 shared papers, 2016–2017 · strength 0.12
  13. Keping Xie · 2 shared papers, 2016–2017 · strength 0.12
  14. Huamin Wang · 1 shared paper, 2020 · strength 0.09
  15. Xiaofeng Zheng · 1 shared paper, 2020 · strength 0.09
  16. Baoan Ji · 1 shared paper, 2020 · strength 0.09
  17. Donghui Li · 1 shared paper, 2020 · strength 0.09
  18. Dacheng Xie · 1 shared paper, 2017 · strength 0.06
  19. Jiawei Du · 1 shared paper, 2017 · strength 0.06
  20. Victoria K. Xie · 1 shared paper, 2017 · strength 0.06
  21. Xiangyu Kong · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.